ZTS valuation has slid sharply, pushing the stock toward its 200‑day moving average support while cash‑flow generation remains robust. Fundamentals still favor a neutral stance pending a clearer catalyst.

Investor reaction is muted after the guidance cuts and Goldman’s neutral coverage, keeping sentiment flat. The market seems to view the valuation dip as a temporary blip rather than a trend shift.

Guidance reductions heighten earnings volatility and expose ZTS to downside risk if its pipeline stalls. Long‑term outlook hinges on sustained growth in animal health, which remains uncertain amid competitive pressure.

Technical indicators show ZTS oversold (RSI ~28) with a bullish divergence and rising volume on recent rallies. These data points suggest a short‑term upside potential despite the valuation drop.